Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $37.52, but opened at $33.69. Tempus AI shares last traded at $32.24, with a volume of 1,851,924 shares changing hands.
Wall Street Analysts Forecast Growth
TEM has been the subject of a number of research analyst reports. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and increased their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a "buy" rating and a $74.00 price target for the company. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $56.00 price objective on shares of Tempus AI in a research report on Tuesday. Finally, Piper Sandler reissued a "neutral" rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Tempus AI has an average rating of "Moderate Buy" and a consensus target price of $56.36.
Get Our Latest Research Report on TEM
Tempus AI Trading Up 9.7 %
The firm has a 50 day simple moving average of $47.68 and a two-hundred day simple moving average of $47.26. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.
Insider Buying and Selling at Tempus AI
In related news, major shareholder Bradley A. Keywell sold 395,800 shares of the firm's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares in the company, valued at $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David R. Epstein sold 620 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 865,041 shares of company stock valued at $35,917,673.
Institutional Investors Weigh In On Tempus AI
Hedge funds and other institutional investors have recently modified their holdings of the stock. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI in the 3rd quarter worth approximately $30,000. Geode Capital Management LLC grew its holdings in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock valued at $7,537,000 after purchasing an additional 539 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at $67,000. Vestor Capital LLC acquired a new position in shares of Tempus AI during the 3rd quarter worth $153,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company's stock worth $1,686,000 after buying an additional 2,765 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
